Coya Therapeutics, Inc.
COYA
Rank in Stocks
#20873
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Share Price
$3.27
Last synced: 2026-11-12
Market Cap
$76.71M
Change (1 day)
1.87%
Change (1 year)
-44.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Coya Therapeutics, Inc. (COYA)
Category
Healthcare
Operating Margin for Coya Therapeutics, Inc. (COYA)
Operating Margin as of November 2026 TTM: -675.34%
According to Coya Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -675.34%. At the end of 2025 the company had an operating margin of -255.05%.
Operating Margin history for Coya Therapeutics, Inc. from 2020 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -675.34% | 164.79% |
| 2025 | -255.05% | -47.45% |
| 2024 | -485.35% | 268.61% |
| 2023 | -131.67% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -99.71% |
US
|
|
| 33.87% | -100.05% |
US
|
|
| -116.04% | -99.83% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.05% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Coya Therapeutics, Inc.'s operating margin
What is Coya Therapeutics, Inc.'s operating margin?
Coya Therapeutics, Inc.'s operating margin is -675.34%, as of Nov 2026.
What was Coya Therapeutics, Inc.'s operating margin in 2025?
In 2025, Coya Therapeutics, Inc.'s operating margin was -255.05%, compared with -485.35% in 2024.
How has Coya Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Coya Therapeutics, Inc.'s operating margin was highest in 2022 (0.00%) and lowest in 2024 (-485.35%).
How does Coya Therapeutics, Inc.'s operating margin compare with similar companies?
Coya Therapeutics, Inc.'s operating margin (-675.34%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.